Concepta PLC myLotus® successful UK launch (6039K)
17 December 2018 - 6:00PM
UK Regulatory
TIDMCPT
RNS Number : 6039K
Concepta PLC
17 December 2018
17 December 2018
Concepta Plc
("Concepta" or the "Company")
myLotus(R) successful UK launch
Concepta Plc (AIM: CPT), the innovative UK healthcare company
and developer of the proprietary self-test platform ("myLotus(R)")
and suite of emerging test products targeting the mobile health
market is pleased to advise on the successful launch in the UK of
its breakthrough myLotus(R) product for women's fertility.
myLotus(R) allows women to self-test to identify their optimal
fertile days thereby improving their chances of naturally getting
pregnant. myLotus(R) enables women to monitor their fertile phase
as part of their menstrual cycle and is the only home test to
'quantitatively' measure personalised hormone levels and the
'rate-of-change' of these levels preceding ovulation to help aid a
natural conception. Users measure, record and track their hormone
levels and follow their fertility journey in an accompanying free
downloadable app.
Whilst awareness, profile and sales of the myLotus(R) device are
just commencing, feedback from early users and fertility bloggers
has been very positive can be viewed online at www.myLotus.com
Discussions have also commenced with 'Key Opinion Leaders' to
advise on the wider use of myLotus(R) especially for women who wish
to carefully monitor their hormonal levels and for those who have
previously struggled to conceive naturally, enabling an alternative
for couples prior to considering more costly IVF treatment.
In addition to the growing myLotus(R) digital UK presence, the
Company is preparing plans for the roll-out of myLotus(R) across
Europe under its CE-mark approval. Commercial discussions have also
commenced with retail providers to make myLotus(R) more broadly
available across the UK.
Matthew Walls, Chairman said: "Although marketing and
communications around myLotus(R) are just beginning, feedback from
the early users has been exceptional. We will be raising awareness
of the value of the myLotus(R) device and its window on fertility
over the coming months via an increased online presence, Key
Opinion Leaders and marketing of our initial fertility case
studies. Further details can be viewed at www.myLotus.com."
Enquiries
Company: www.conceptaplc.com, Product: www.myLotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
Yellow Jersey PR Limited (Financial PR)
Felicity Winkles Tel: +44 (0) 774 884 3871
About Concepta Plc:
Concepta Plc is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalised mobile health market with a primary focus on
increasing a woman's chances of getting pregnant naturally and for
unexplained infertility in women.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to help women
conceive naturally by identifying their window of fertility and
optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of consumers won't typically be offered medical
intervention until 12 months of unsuccessfully trying, with IVF
typically not offered until two years. Research indicates couples
start to take positive action ahead of this time with little
medical support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PRLUNUKRWOAUAAA
(END) Dow Jones Newswires
December 17, 2018 02:00 ET (07:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024